BILE ACIDS IN LOWER AIRWAYS AS A NOVEL INDICATOR OF AIRWAY MICROBIOTA CHANGES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

- 4
- Jose A. Caparrós-Martín^{1,2,§}, Montserrat Saladié^{2,§}, S. Patricia Agudelo Romero^{1,3}, Kristy S. Nichol⁴, F. Jerry Reen^{5,6}, Yuben Moodley^{7,8,9,10}, Siobhain
- 7 Mulrennan^{10,11}, Stephen M. Stick^{1,3,12}, Peter A Wark⁴ and Fergal O'Gara^{1,2,13}.
- 8
- ⁹ ¹Wal-yan Respiratory Research Centre. Telethon Kids Institute, Perth, Western
- 10 Australia, Australia.
- ¹¹ ²Curtin Health Innovation Research Institute (CHIRI), Curtin University, Perth,
- 12 Western Australia, Australia.
- ¹³ ³The University of Western Australia, Perth, Western Australia, Australia.
- ¹⁴ ⁴Immune Health Program, Hunter Medical Research Institute, University of
- 15 Newcastle, Newcastle, New South Wales, Australia.
- ⁵School of Microbiology, University College Cork, Cork, Ireland.
- ¹⁷ ⁶Synthesis and Solid-State Pharmaceutical Centre, University College Cork,
- 18 Cork, Ireland.
- 19 ⁷Centre for Respiratory Health, School of Biomedical Science, The University of
- 20 Western Australia, Nedlands, Western Australia, Australia.
- ⁸Cell Biology Group, Institute for Respiratory Health, Nedlands, Western
 Australia, Australia.
- ²³ ⁹Department of Respiratory Medicine, Fiona Stanley Hospital, Murdoch,
- 24 Western Australia, Australia.
- ¹⁰UWA Medical School, The University of Western Australia, Perth, Western
- 26 Australia, Australia.
- 27 ¹¹Cystic Fibrosis Research Unit, Institute for Respiratory Health, Nedlands,
- 28 Western Australia, Australia.
- ¹²Department of Respiratory Medicine, Princess Margaret Hospital for Children,
- 30 Perth, Western Australia, Australia.
- ³¹¹³BIOMERIT Research Centre, School of Microbiology, University College Cork,
- 32 Cork, Ireland.
- 33
- [§] These authors contributed equally to the manuscript

35

- 36 Correspondence to:
- 37 Professor Fergal O'Gara; BIOMERIT Research Centre, School of Microbiology,
- 38 University College Cork, T12 K8AF Cork, Ireland. Tel.: +353-21-4901315; Fax:
- 39 +353-21-4275934 Email: <u>f.ogara@ucc.ie</u>
- 40

41 Abstract

Background. Chronic obstructive pulmonary disease (COPD) is a complex disorder with a high degree of interindividual variability. Gastrointestinal dysfunction is common in COPD patients and has been proposed to influence the clinical progression of the disease. Using the presence of bile acid(s) (BA) in bronchoalveolar lavage fluid (BAL) as a marker of gastric aspiration, we evaluated the relationships between BAs, clinical outcomes, and bacterial lung colonisation.

49 **Methods.** We used BAL specimens from a cohort of COPD patients and 50 healthy controls. Bile acids were profiled and quantified in BAL supernatants 51 using mass spectrometry. Microbial DNA was extracted from BAL cell pellets 52 and quantified using qPCR. We profiled the BAL microbiota using an amplicon 53 sequencing approach targeting the V3-V4 region of the 16S rRNA gene.

54 **Results.** Detection of BAs in BAL was more likely at earliest clinical stages of 55 COPD and was independent of the degree of airway obstruction. BAL 56 specimens with BAs demonstrated higher bacterial biomass and lower diversity. 57 Likewise, the odds of recovering bacterial cultures from BAL were higher if BAs 58 were also detected. Detection of BAs in BAL was not associated with either 59 inflammatory markers or clinical outcomes. We also observed different bacterial 60 community types in BAL, which were associated with different clinical groups, 61 levels of inflammatory markers, and the degree of airway obstruction.

62 **Conclusion.** Detection of BAs in BAL was associated with different parameters 63 of airway ecology. Further studies are needed to evaluate whether BAs in BAL 64 can be used to stratify patients and for predicting disease progression 65 trajectories.

66

Keywords. Microbiota, chronic obstructive pulmonary disease, Bile acids,
gastroesophageal reflux disease.

69

70 Introduction

Chronic obstructive pulmonary disease (COPD) is a progressive lung condition 71 72 associated with chronic inflammation, airflow obstruction, and irreversible damage of the alveolar walls^{1,2}. The development of COPD is linked to long-73 term exposure to tobacco smoke and airborne pollutants that irritate the 74 airways². The clinical evolution of COPD is dictated by worsening episodes of 75 variable aetiology and severity called exacerbations². Other factors, such as 76 microbial dynamics and airway colonisation, airway hyper-reactivity, and 77 78 immune and gastroesophageal dysfunction have all been shown to influence 79 disease severity and progression².

80 The prevalence of functional gastrointestinal pathology in patients with chronic lung disease is high³. A common extrapulmonary manifestation in patients with 81 COPD is gastroesophageal reflux disease (GERD)⁴. Numerous epidemiological 82 83 studies have shown a robust relationship between GERD and increased incidence of COPD exacerbations⁵⁻⁸. This suggests that reflux may modulate 84 85 disease severity in COPD. The mechanisms through which GERD could 86 aggravate the pathophysiology of COPD are unknown, but it may involve the 87 translocation of gastric metabolites and/or microorganisms into the lower airways through a reflux-microaspiration process⁹. 88

89 Bile acids (BAs) are host metabolites involved in fat digestion. Apart from their 90 role as fat emulsifiers, BAs have antimicrobial, endocrine and immune 91 regulatory properties, and modulate the expression of pathogenesis-related genes in bacterial pathogens^{10,11}. Several studies have identified BAs in 92 93 bronchoalveolar lavage fluid (BAL) obtained from patients with different 94 respiratory pathologies³. When detected in BAL, BAs have been associated 95 with pathophysiologic events in chronic lung disease. Thus, the presence of 96 BAs in BAL has been linked to airway inflammation in patients with cystic fibrosis¹²⁻¹⁵, lung transplant (LTx) recipients¹⁶⁻¹⁸, and children with respiratory 97 symptoms¹⁶. In LTx recipients, detection of BAs in BAL is also a risk factor for 98 99 allograft dysfunction and mortality¹⁷.

The lung microbiota originates from the aspiration of pharyngeal commensals¹⁹, through a process that also calibrates the lung immune tone²⁰. In COPD, the composition of the lung microbiota represents a source of clinical heterogeneity. Different microbial assemblages or endotypes are linked to specific COPD clinical phenotypes, which determine treatment response and disease progression trajectories^{21,22}. Whether and how bacterial aspiration is clinically relevant for the progression of COPD is unknown.

107 In this study, we evaluated associations between detection of BAs in BAL, 108 parameters of airway ecology and clinical outcomes. We used a cohort of BAL 109 specimens collected from clinically stable COPD patients at different stages of 110 the disease, and healthy controls. Detection of BAs in BAL was robustly 111 associated with parameters of airway ecology. Overall, our data suggest that 112 detection of BAs in BAL indicates processes associated with airway microbial 113 colonisation in COPD.

114

115 Results

116 **Study population**

117 This is a retrospective study of 166 bronchoalveolar lavage (BAL) specimens 118 collected from 108 patients with COPD (GOLD1-4) and healthy non-smokers 119 (nSC, 38) and healthy smoker (SC, 20) controls. Bronchoalveolar lavage samples were collected as previously described²³. Patients with COPD were 120 121 stable, with no change in medications or acute exacerbations in the previous 6 122 weeks. Healthy controls had spirometry in the normal range (FEV1>80% 123 predicted, FEV1/FVC > 0.7), and no history of chronic lung disease. Patient 124 demographics are provided in Table 1.

125

126 **Detection of bile acids in BAL is associated with early stages of COPD.**

We detected bile acids (BAs) in 67 (40.4%) BAL specimens (median concentration [interquartile range (IQR)], 0.24 [0.13-0.47] μ M) (Table S1). The concentration of BAs in BAL from COPD patients was higher than in healthy donors (median [IQR] in controls, 0 [0-0] μ M; median [IQR] in COPD patients, 0.007 [0-0.09] μ M, Wilcoxon Rank Sum Test (WRST), *p*=0.0006, r=0.27) (Figure S1). In our cohort, detection of BAs in BAL was associated with patient age but not with the degree of airway obstruction (Figure S2).

134 Detection of BAs was more likely in BAL collected from COPD patients than from healthy controls (odds ratio (OR) [95% confidence interval], 3.98 [1.90-135 136 8.33] p=0.0002). Eight of 38 non-smoker healthy controls (21%), 4 of 20 smoker 137 healthy controls (20%), 14 of 25 COPD patients from GOLD stage I (56%), 19 138 of 32 COPD patients from GOLD stage II (59%), 18 of 36 COPD patients from 139 GOLD stage III (50%), and 4 of 15 COPD patients from GOLD stage IV (27%), 140 had BAs in BAL. Compared to the nSC group, the likelihood for detecting BAs 141 in BAL was increased in early stages of COPD (OR [95% confidence interval], GOLD1 4.77[1.57-14.48] p=0.006, GOLD2 5.48[1.91-15.69] p=0.001, GOLD3 142 143 3.75[1.36-10.37] p=0.01, GOLD4 1.36[0.34-5.45] p=0.66) (Figure 1). We 144 obtained similar results after controlling for the degree of airway obstruction (FEV₁/FVC ratio) or patient age (Figure S3). 145

146

147 Relationships between the presence of BAs in BAL and clinical outcomes.

COPD patients with or without BAs in BAL, demonstrated similar levels of white 148 cells in their lungs (median (x10⁶ cells/mL) [IQR], BAs detected 0.36 [0.25-0.57], 149 no BAs detected 0.18 [0.16-0.63], WRST, p=0.3, r=0.24), with no differences in 150 viability (median (x10⁶ cells/mL) [median (% of viable cells) [IQR)], BAs 151 152 detected 90 [83-93], no BAs detected 92 [77-95], WRST, p=0.75, r=0.08). 153 Similarly, there was no difference in the proportion of neutrophils in BAL (median (%) [IQR], BAs detected 68.4 [56.3-84.3], no BAs detected 62.6 [43.3-154 74.3], WRST, p=0.1, r=0.16). Conversely, detection of BAs was linked to a 155 higher bacterial burden in BAL (median (Log10 16S copies uL⁻¹ of DNA extract) 156 157 [IQR], BAs detected 4.54 [3.98-5.30], no BAs detected 4.14 [3.60-4.76], WRST, 158 p=0.01, r=0.25) (Figure S4). In the case of the healthy control groups (smokers 159 and non-smokers), detection of BAs in BAL was not linked to differences in the 160 proportion of infiltrated neutrophils, number and viability of white blood cells, or 161 bacterial load in BAL (Figure 2A).

In patients with COPD, the presence of BAs in BAL was not correlated with clinical outcomes, including the ratio of FEV₁ to FVC (median [IQR], BAs detected 57 [48-67], no BAs detected 52 [42-64], WRST, p=0.32, r=0.1), quality of life (COPD assessment test, CAT) (median [IQR], BAs detected 13 [10-16], no BAs detected 15 [7-19],WRST, p=0.95, r=0.01), and either number of exacerbations (median [IQR], BAs detected 4 [2-7], no BAs detected 3 [1-

168 5],WRST, p=0.45, r=0.11), number of antibiotic rounds (median [IQR], BAs 169 detected 2 [1-5], no BAs detected 2 [1-4], WRST, p=0.58, r=0.08), or number of

170 oral corticosteroids rounds (median [IQR], BAs detected 1 [0-2], no BAs

171 detected 0 [0-1],WRST, *p*=0.44, r=0.12) (Figure S5).

172

173 Associations between the COPD BAL microbiota and clinical outcomes.

We analysed the bacterial profiles of 104 BAL samples with bacterial biomass above the cut-off defined by the negative extraction controls (Figure S6). These taxonomic profiles were dominated by operational taxonomic units (OTUs) assigned to the *Streptococcus* (mean relative abundance (standard deviation), 20.19% (17.79)) and *Haemophilus* (13.22% (28.58)) taxa (Figure S7).

179 In our cohort, alpha (within sample) diversity was negatively associated with bacterial biomass (β -0.44, Adjusted R² 0.14, F(1,102)=17.20, p=0.00007) and 180 the percentage of neutrophils in BAL (β -0.01, Adjusted R² 0.10, F(1,97)=12.41, 181 182 p=0.0006) (Figure S8). We obtained similar results when the data from healthy 183 controls (both smokers and non-smokers) was excluded from the linear models 184 (Figure S9). Despite the observed relationships between microbial parameters 185 and inflammation in BAL from COPD patients, the degree of airway obstruction 186 was not predicted by either the bacterial diversity (Shannon index, β 2.66, 187 Adjusted R^2 0.02, F(1,70)=2.17, p=0.14), or the bacterial biomass in BAL (Log10 16S copies μ L⁻¹ of DNA extract, β -1.70, Adjusted R² 0.00, 188 F(1,70)=0.71, p=0.40) (Figure S10A-B). Likewise, guality of life or number of 189 190 exacerbations were not correlated with either bacterial load or diversity in BAL (Figure S10C-F). Conversely, BAL specimens containing BAs demonstrated 191 192 reduced diversity (median [IQR], BAs detected 1.90 [0.78-2.50], no BAs detected 2.42 [1.82-2.77]; WRST, p=0.01, r=0.24), and increased odds for 193 194 isolating microorganisms in cultures from BAL (any microorganism, OR 195 2.41[1.15-5.02] *p*=0.02) (Figure 2B-C).

We used Dirichlet Multinomial Mixtures to classify the BAL-associated microbial communities and observed 3 different clusters or ecotypes (Figure 3 and Figure S11). These 3 ecotypes showed contrasting levels of BAL-associated bacterial biomass (Figure 3C). At community level, two OTUs assigned to the *Streptococcus* and *Haemophilus* taxa were the more abundant entities defining

each community-based cluster (Figure S12). Interestingly, each ecotype was 201 202 associated with different clinical outcomes as well as specific clinical groups 203 (Figure 3 and Figure S13). Ecotypes I and II occurred in samples from both 204 healthy controls and COPD patients, although it is true that ecotype II was less 205 likely in healthy controls (Figure S13). Both ecotype I and II were dominated by 206 Streptococcus, however ecotype II had a less evenly distributed community 207 composition (Figure 3B). Clinically, the transition from ecotype I to ecotype II 208 was associated with a progressive increase in airway inflammation and higher 209 degree of obstructive impairment on spirometry (Figure 3D-E). On the other 210 hand, the Haemophilus-dominated community (ecotype III) was only observed 211 in BAL specimens collected from COPD patients (Figure S13). Ecotype III was 212 also associated with a higher percentage of neutrophils in BAL (Figure 3E). 213 None of the 3 ecotypes was significantly associated with either specific GOLD 214 stages or BA detection in BAL (Figure S13).

215

216 **Discussion**

217 Gastrointestinal manifestations are commonly observed in patients with COPD, and they have been linked to disease heterogeneity⁵. Thus, gastroesophageal 218 219 reflux disease (GERD), which could lead to the aspiration of gastric contents, is associated with a "frequent exacerbator" phenotype⁵⁻⁸. In patients with COPD, 220 221 several of the physiological barriers preventing the gastric contents reaching the airways are impaired³. Moreover, most COPD patients smoke or are frequently 222 223 treated with beta-agonists and theophyllines, which affect the physiology of the oesophageal sphincters³. These functional defects are therefore expected to 224 225 facilitate reflux and aspiration of gastric contents, and they likely represent a 226 functional link between the gastrointestinal tract and respiratory disease. In this 227 study, we evaluated the clinical significance of the presence of BAs in BAL and 228 their impact on BAL-associated microbiota. Bile acids are gastric metabolites 229 that, when observed in the lower airways, are considered a gastric marker for 230 aspiration⁹. In our cohort, the likelihood of detecting BAs in BAL was 231 significantly increased in patients with early-stage COPD disease compared to 232 healthy individuals. This observation was independent of the degree of airway 233 obstruction present but was positively linked to patient age. Past publications 234 have reported contrasting results regarding a relationship between the

presence of BAs in BAL, and lung function^{12,14,16,24}. This discrepancy between 235 236 studies suggests that while lung deterioration could facilitate BAs detection in 237 BAL (e.g. mucociliary clearance impairment), extrapulmonary mechanisms are 238 also involved³. We also detected BAs in 20-21% of BAL samples collected from 239 healthy controls, and this was independent of smoking status. A previous study reported BAs in 13% of sputum samples from healthy individuals¹³, supporting 240 the notion that BAs reach the airways in the absence of a respiratory pathology. 241 242 Likewise, this 10-20% detection range in healthy subjects could be explained by the estimated 10-30% prevalence of GERD in the Western population²⁵. 243

244 Persistent airway inflammation is a common feature in chronic lung disease. Although tobacco smoke is the major driver of inflammation in COPD lungs, 245 inflammatory markers remain elevated even after the cessation of smoking²⁶. 246 247 Thus, additional factors are likely involved in maintaining the inflammatory 248 milieu in COPD lungs. Bile acids have been robustly linked to inflammation and poor clinical outcomes in different respiratory disorders^{9,12-14,16-18,24}, and they 249 could provide a link between GERD and COPD disease severity⁵. In our study, 250 251 the percentage of neutrophils in COPD BAL regardless of BAs presence was 252 comparable, suggesting that BAs are not involved in establishing the 253 inflammatory landscape of COPD lungs. Similarly, we did not observe a 254 relationship between the presence of BAs in BAL and clinical outcomes. These 255 results are in line with a previous study whose findings did not support a role of BAs in COPD exacerbations²⁷. We however observed a robust association 256 between BAs and ecological parameters in BAL. Aspiration can shape the 257 COPD lung microbiota²⁸, and is a mechanism for pulmonary colonisation¹⁹. 258 Likewise, bacterial, and viral infections are known triggers of exacerbations in 259 COPD²⁹. In our study, COPD BAL samples with BAs demonstrated higher 260 261 bacterial load and lower diversity than specimens without BAs. Additionally, the 262 probability for a positive microbial culture from BAL was significantly increased if 263 BAs were also detected. Considering this, future studies are required to clarify 264 whether the known relationship between GERD and COPD exacerbations could 265 be explained by reflux increasing the risk of aspiration of microbial pathogens. The lung microbiome plays an important role in the progression of COPD^{21,22}. 266

We found that BAL bacterial biomass and diversity were negatively correlated with the percentage of infiltrated neutrophils. However, clinical outcomes were

independent of bacterial community descriptors in BAL. This unexpected
 observation supports previous studies demonstrating that clinical responses in
 COPD depends on particular microbial community signatures^{21,22}, rather than
 on the overall structure of the bacterial community.

273 We also examined the microbial communities present in BAL. Using cluster 274 analysis and likelihood estimators, we identified three community types, that 275 were correlated with contrasting degrees of airway obstruction and 276 inflammation, and different clinical groups. We found that Haemophilus-277 dominated communities were characterized by elevated biomass, and were 278 also linked to the highest percentage of neutrophils in BAL. This community 279 type was exclusively observed in COPD BAL samples. This result is in line with 280 previous work in COPD demonstrating that Haemophilus dominance is consistently associated with neutrophilic inflammation^{21,22}. We also identified 281 282 two Streptococcus-dominated microbial community types, which could 283 represent different states of the balanced microbiome profile previously described in COPD sputum^{21,22}. Streptococcus dominance was observed in 284 285 BAL from both healthy controls and COPD patients, and it was not linked to 286 specific clinical stages of the disease. Interestingly, both ecotypes showed 287 contrasting patterns of microbial distribution, with the less evenly distributed 288 signature associated with a progressive increase in airway obstruction and 289 inflammation. Detection of BAs in BAL did not correlate with specific microbial 290 assemblages. This result suggests that although bacteria and BAs could access 291 the airways through the same physiological process, additional factors 292 determine the type of bacterial community thriving in the lungs.

293 An obvious limitation of our study is its observational nature, which does not 294 allow causality to be established. Likewise, participants did not undergo 295 gastroesophageal reflux monitoring. Thus, we cannot confirm the physiological 296 alteration mediating BAs intrusion into the airways. Although the physiological 297 process underlying the translocation of BAs into the lungs is not relevant for the 298 associations shown in the present study, BAs in BAL are considered a marker of gastric aspiration⁹. Lastly, BAs and the microbial profiles could be 299 300 confounded by salivary contamination during bronchoscopy. Although we 301 cannot rule out this possibility, our results demonstrating an association

between detection of BAs and specific clinical groups are unlikely to be drivenby a contamination signal.

Overall, in this cross-sectional study, we show that detection of BAs in BAL is associated with early stages of COPD, and correlated with parameters of airway ecology, but not with clinical outcomes. Future longitudinal studies are needed to determine whether the presence of BAs in BAL at early clinical stages of COPD is a useful approach to stratify COPD patients (e.g. to capture those subjects in a worse disease progression trajectory).

310

311 **FIGURE LEGENDS.**

Figure 1. Forest plots showing the odds of detecting BAs in BAL in the different
population groups. Odds ratio are represented with 95% pointwise confidence
interval.

315

316 Figure 2. A-B. Boxplots overlaid with density plots (blue) showing the 317 relationship between BAs detection in BAL and bacterial load (A), and the 318 diversity of the BAL-associated microbial communities (B). Individual values for 319 each BAL specimen are represented with red dots. Notches in the boxplots 320 represent 95% confidence interval for the sample median. Statistical 321 significance was assessed using the Wilcoxon rank sum test. For each 322 comparison, the corresponding p-value (p) is shown in the graph. C. Marginal 323 effect of BAs detection in BAL on the odds of observing positive microbial 324 cultures from BAL with pointwise 95% confidence intervals. Predicted 325 probabilities were calculated from a logistic regression model.

326

327 Figure 3. A. Scatter plot showing the projection of the BAL-associated bacterial 328 compositional profiles in the first two components of the principal component 329 analysis. Samples are labelled accordingly with the cluster membership. B. 330 Heatmap summarising the top 10 OTUs ordered based on their contribution to 331 the Dirichlet components. Narrow columns represent the square-root of the 332 OTU relative abundance, while wide columns represent the mean value of the 333 Dirichlet component for each mixture. C-E. Barplots overlaid with density curves 334 representing differences in bacterial load (C), FEV1/FVC ratio (D), and the 335 percentage of neutrophils in BAL (E), relative to the indicated microbial

community cluster. Red dots represent observed values for each BAL
specimen. Statistical significance was assessed using the Wilcoxon rank sum
test and p-values corrected for multiple comparisons using the Bonferroni
method.

340

341 Methods

Isolation of microbial DNA from BALF, 16S metabarcoding, sequencing of
 the amplicon pools, and processing of the sequencing data.

344 We obtained cell pellets from 163 out of the 166 BALF specimens through high-345 speed centrifugation of 1-2 mL of BALF. Reagent-related contaminants were 346 controlled by sequencing negative extraction controls. Extraction of microbial DNA and amplicon-based bacterial profiling targeting the V3-V4 region of the 347 348 16S rRNA gene were performed blinded to clinical data as we described³⁰. In 349 this project, we obtained 19,236,207 single reads with a good base calling 350 accuracy (96% of sequences with mean Phred-like Q-score greater than or equal to 30). Raw sequencing data was processed as we described³⁰. Quality-351 352 based pre-processing resulted in 8,538,607 paired-end reads (average length 353 405 bp), with >94% of the reads having a mean Phred-like Q-score greater than 354 or equal to 35. Pre-processed joint reads were analysed following the SILVAngs pipeline^{31,32} as we described³⁰. For taxonomic classification we used the last 355 356 release of the standardised SILVA SSU taxonomy (release 138.1) as reported³⁰. Following this processing pipeline, amplicon sequencing data was 357 358 assigned to 1,280 Operational Taxonomic Units (OTUs).

359

Removal of the potential background contaminants determined by negative extraction controls.

362 Bacterial burden in negative processing controls was used to determine the 363 background noise associated with our experimental conditions. For 17 DNA 364 extracts, we did not have enough DNA for assessing bacterial load, and the 365 taxonomy profiles from these BALF samples were therefore removed from the final dataset. We set the background cut-off to 4,100 16S DNA copies μL^{-1} of 366 367 DNA extract, which lies three standard deviations from the mean bacterial load in the negative extraction controls (mean 1,722.58, standard deviation 777.86, 368 16S DNA copies µL⁻¹ DNA extract) (Figure S14). In our dataset, 104 DNA 369

370 extracts from BAL had bacterial burden above the background cut-off. These 371 104 DNA extracts were therefore considered for further analysis on the basis 372 that, the associated microbial profiles, are more likely to represent a true 373 biological signal. The taxonomic table was then processed to eliminate 374 singletons, reads classified as Chloroplast (mean relative abundance (standard 375 deviation), 0.005% (0.03)), Mithocondria (0.00004% (0.0002)) or Eukaryota taxa (0.0000006% (0.000009)), and no classified reads (0.001% (0.002)). Taxa 376 377 representing less than 0.01% across all samples were also removed. Potential contaminants introduced during the processing of the samples were estimated 378 379 using the R package *decontam*³³ as we previously described³⁰. We detected and removed from the OTU table, 8 OTUs potentially arising from 380 381 environmental contamination (Table S2). These filtering steps removed 1,127 382 OTUs from the unfiltered dataset, resulting in a OTU table with 153 unique 383 taxonomy paths. Procrustes analysis confirmed that these filtering steps did not 384 significantly impact the overall structure of the unfiltered microbial profiles 385 (Table S3 and Figure S16). We obtained a good correspondence between 386 clinical microbiology data from BAL cultures and the taxonomic profiles obtained 387 using molecular methods (Table S4).

388

389 Quantitative analysis of bacterial burden in BAL.

390 We used a TaqMan® probe to estimate bacteria burden in DNA extracts as 391 described in our previous publication³⁰.

392

393 Quantitative profiling of bile acids in BAL.

We extracted bile acids from spun BAL supernatants using solid-phase separation¹². For identification and quantification of the different bile acid analytes we used mass spectrometry as we previously described^{12,34}.

397

398 Statistical analyses.

399 Statistical analyses and graphical representations were done in R (Version 400 4.0.2). Normality of data distribution the data was evaluated using the Shapiro-401 Wilk test. When data did not follow a normal distribution, we evaluated 402 differences between group medians using the Wilcoxon Rank Sum Test. Linear 403 models were computed in R using the *Im* function. The assumption of

homoscedasticity of the residuals and the absence of high influential data points
were confirmed using regression diagnostics. Shannon diversity index was
calculated with the *diversity* function of the R package vegan. For cluster
analysis of the BAL-associated bacterial communities we used Dirichlet
Multinomial Mixtures models³⁵. The probability threshold for statistical
significance was set at 0.05.

410

411 **Data availability.**

412 All the sequencing data generated in this study have been deposited in the 413 Sequencing Read Archive under the Bioproject accession PRJNA820972.

414

415 **Ethics statement.**

416 Ethical approval was obtained from the Hunter New England LHD Ethics

417 committee [Mechanisms of Inflammatory airways disease (05/08/10/3.09)].

418

419 Acknowledgments.

420 We gratefully acknowledge the patients and participants for donating BAL fluid 421 to support this study. This work was funded in part by grants awarded by the 422 Health Research Board (HRB-ILP-POR-2019-004), the Irish Thoracic Society 423 (MRCG-2018-16 and MRCG-2014-6), the US Cystic Fibrosis Foundation 424 (OGARA1710), Australian NHMRC 2020 Synergy grant (APP1183640), the Glenn Brown Memorial Grant 2017 (The Institute for Respiratory Health, Perth, 425 426 Australia), the European Commission (EU-634486), Science Foundation Ireland 427 (SSPC-2/PharM5, 13/TIDA/B2625, 14/TIDA/2438 and 15/TIDA/2977) and 428 Enterprise Ireland Commercialisation Fund (CF-2017-0757-P). J.A.C.-M. thanks the director of the Curtin Health and Innovation Research Institute (CHIRI) 429 430 Professor John Mamo and the CHIRI laboratory manager Dr Rob Stuart for granting access to the CHIRI laboratory facilities, and the mass-spectrometry 431 432 officer Dr Ben Hunter for providing technical support with the mass 433 spectrometer.

434

Author Contributions: Conceptualization, F.O.G., J.A.C.-M and F.J.R.;
Methodology, M.S. and J.A.C.-M.; Formal Analysis, J.A.C.-M. and S.P.A.-R.;
Investigation, J.A.C.-M. and M.S.; Resources, P.A.W., Y.M., S.M. and S.M.S.;

438 Writing-Original Draft Preparation, J.A.C.-M. and F.O.G.; Writing – Review & 439 Editing, J.A.C.-M., M.S., S.P.A.-R., N.K., F.J.R., Y.M., S.M., S.M.S., P.A.W. and

- 440 F.O.G.; Visualization, J.A.C.-M.
- 441

442 Conflicts of Interests: The authors declare no conflict of interest, financial or
443 otherwise. The research funders had no role in study design, data collection
444 and analysis, decision to publish, or preparation of the manuscript.

445 446

FEV1/FVC, mean (SD); Age, mean (SD); Sex (% males): number of patients number of patients number of patients GOLD1 72.29(7.55); 21 64.52(11.52); 25 40%: 25 GOLD2 57.77(10.70); 32 72.06(7.14); 31 53%; 32 GOLD3 69.03(10.74); 36 67%; 36 49.53(11.96); 36 60%; 15 GOLD4 61.93(10.85); 15 34.71(9.31); 14 nSC 76.15(7.64); 33 57.63(17.12); 38 42%; 38 SC 75.76(13.61); 17 51.85(18.22); 20 55%; 20 F=53.91, *** F=9.17, ** Statistical test χ^2 10.82, n.s.

447

448**Table 1. Patient demographics.** We used a Joint F-test for assessing449differences in the degree of airway obstruction and patient age. A chi-square450test of independence was used to evaluate differences in patient sex across the451different clinical groups. **, p<0.01; ***, p<0.001.</td>

453 **References:**

454

452

455

456 1. Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive
457 pulmonary disease. *Lancet* 2022; **399**(10342): 2227-42.

458 2. GOLD. Global Strategy for the Diagnosis, Management and Prevention of

459 COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2021.; 2021.

- 460 3. Houghton LA, Lee AS, Badri H, DeVault KR, Smith JA. Respiratory disease 461 and the oesophagus: reflux, reflexes and microaspiration. *Nat Rev Gastroenterol*
- 462 *Hepatol* 2016; **13**(8): 445-60.

463 4. Casanova C, Baudet JS, del Valle Velasco M, et al. Increased gastro-

464 oesophageal reflux disease in patients with severe COPD. *Eur Respir J* 2004; 23(6):
841-5.

466 5. Huang C, Liu Y, Shi G. A systematic review with meta-analysis of

gastroesophageal reflux disease and exacerbations of chronic obstructive pulmonary
disease. *BMC Pulm Med* 2020; **20**(1): 2.

469 6. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic
470 obstructive pulmonary disease. *N Engl J Med* 2010; **363**(12): 1128-38.


471 7. Terada K, Muro S, Sato S, et al. Impact of gastro-oesophageal reflux disease
472 symptoms on COPD exacerbation. *Thorax* 2008; 63(11): 951-5.


- 8. Rascon-Aguilar IE, Pamer M, Wludyka P, et al. Role of gastroesophageal reflux
 symptoms in exacerbations of COPD. *Chest* 2006; **130**(4): 1096-101.
- 475 9. Lee AS, Lee JS, He Z, Ryu JH. Reflux-Aspiration in Chronic Lung Disease. Ann
 476 Am Thorac Soc 2020; 17(2): 155-64.

- 477 10. Reen FJ, Flynn S, Woods DF, et al. Bile signalling promotes chronic respiratory
 478 infections and antibiotic tolerance. *Sci Rep* 2016; 6: 29768.
 479 110 Charles Market and Article and A
- 479 11. Chen ML, Takeda K, Sundrud MS. Emerging roles of bile acids in mucosal
 480 immunity and inflammation. *Mucosal Immunol* 2019; 12(4): 851-61.
- 481 12. Caparrós-Martín JA, Saladié M, Agudelo-Romero P, et al. Detection of Bile
- 482 Acids in Bronchoalveolar Lavage Fluid Defines Early Pathobiological Events in Infants
- 483 with Cystic Fibrosis. 2022. s. Available at
- 484 SSRN: <u>https://ssrn.com/abstract=4081064</u> or <u>http://dx.doi.org/10.2139/ssrn.4081064</u>
- 485
- 486 13. Pauwels A, Decraene A, Blondeau K, et al. Bile acids in sputum and increased
- 487 airway inflammation in patients with cystic fibrosis. *Chest* 2012; **141**(6): 1568-74.
- 488 14. Caparros-Martin JA, Flynn S, Reen FJ, et al. The Detection of Bile Acids in the
- 489 Lungs of Paediatric Cystic Fibrosis Patients Is Associated with Altered Inflammatory
 490 Patterns. *Diagnostics (Basel)* 2020; **10**(5).
- 491 15. Flynn S, Reen FJ, Caparros-Martin JA, et al. Bile Acid Signal Molecules
- 492 Associate Temporally with Respiratory Inflammation and Microbiome Signatures in
- 493 Clinically Stable Cystic Fibrosis Patients. *Microorganisms* 2020; **8**(11).
- Rosen R, Lurie M, Kane M, et al. Risk Factors for Bile Aspiration and its Impact
 on Clinical Outcomes. *Clin Transl Gastroenterol* 2021; **12**(12): e00434.
- 496 17. Urso A, Leiva-Juarez MM, Briganti DF, et al. Aspiration of conjugated bile
- 497 acids predicts adverse lung transplant outcomes and correlates with airway lipid and
- 498 cytokine dysregulation. J Heart Lung Transplant 2021; 40(9): 998-1008.
- 499 18. Vos R, Blondeau K, Vanaudenaerde BM, et al. Airway colonization and gastric
 500 aspiration after lung transplantation: do birds of a feather flock together? *J Heart Lung*501 *Transplant* 2008; 27(8): 843-9.
- 502 19. Dickson RP, Erb-Downward JR, Freeman CM, et al. Bacterial Topography of 503 the Healthy Human Lower Respiratory Tract. *mBio* 2017; **8**(1).
- 20. Wu BG, Sulaiman I, Tsay JJ, et al. Episodic Aspiration with Oral Commensals
- 505 Induces a MyD88-dependent, Pulmonary T-Helper Cell Type 17 Response that
- 506 Mitigates Susceptibility to Streptococcus pneumoniae. *Am J Respir Crit Care Med*507 2021; 203(9): 1099-111.
- 508 21. Wang Z, Locantore N, Haldar K, et al. Inflammatory Endotype-associated
- Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and
 Exacerbations: A Multicohort Longitudinal Analysis. *Am J Respir Crit Care Med* 2021;
 203(12): 1488-502.
- 512 22. Dicker AJ, Huang JTJ, Lonergan M, et al. The sputum microbiome, airway
- inflammation, and mortality in chronic obstructive pulmonary disease. J Allergy Clin *Immunol* 2021; 147(1): 158-67.
- 515 23. Lokwani R, Wark PAB, Baines KJ, Barker D, Simpson JL. Hypersegmented
 516 airway neutrophils and its association with reduced lung function in adults with
- 517 obstructive airway disease: an exploratory study. *BMJ Open* 2019; **9**(1): e024330.
- 518 24. Blondeau K, Mertens V, Vanaudenaerde BA, et al. Gastro-oesophageal reflux
 519 and gastric aspiration in lung transplant patients with or without chronic rejection. *Eur*520 *Respir J* 2008; **31**(4): 707-13.
- 521 25. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of
- 522 gastro-oesophageal reflux disease: a systematic review. *Gut* 2014; 63(6): 871-80.
 523 26. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS,
- 523 26. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS,
 524 Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and
- 524 Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD 525 asymptometric smokers. *Eur Pagnir I* 2005: **26**(5): 825-45
- 525 asymptomatic smokers. *Eur Respir J* 2005; **26**(5): 835-45.

- 526 27. Hashemi-Bajgani SM, Abbasi F, Shafahi A, Yazdani R, Samareh Fekri M.
- 527 Association of Bile Acid and Pepsin Micro-aspiration with Chronic Obstructive
- 528 Pulmonary Disease Exacerbation. *Tanaffos* 2019; **18**(1): 52-7.
- 529 28. Pragman AA, Lyu T, Baller JA, et al. The lung tissue microbiota of mild and
- 530 moderate chronic obstructive pulmonary disease. *Microbiome* 2018; **6**(1): 7.
- 531 29. Bouquet J, Tabor DE, Silver JS, et al. Microbial burden and viral exacerbations
 532 in a longitudinal multicenter COPD cohort. *Respir Res* 2020; **21**(1): 77.
- 533 30. Saladie M, Caparros-Martin JA, Agudelo-Romero P, Wark PAB, Stick SM,
- 534 O'Gara F. Microbiomic Analysis on Low Abundant Respiratory Biomass Samples;
- Improved Recovery of Microbial DNA From Bronchoalveolar Lavage Fluid. *Front Microbiol* 2020; 11: 572504.
- 537 31. Klindworth A, Pruesse E, Schweer T, et al. Evaluation of general 16S ribosomal
- 538 RNA gene PCR primers for classical and next-generation sequencing-based diversity
 539 studies. *Nucleic Acids Res* 2013; **41**(1): e1.
- 540 32. Quast C, Pruesse E, Yilmaz P, et al. The SILVA ribosomal RNA gene database
- 541 project: improved data processing and web-based tools. *Nucleic Acids Res* 2013;
- 542 **41**(Database issue): D590-6.
- 543 33. Davis NM, Proctor DM, Holmes SP, Relman DA, Callahan BJ. Simple
- statistical identification and removal of contaminant sequences in marker-gene and
 metagenomics data. *Microbiome* 2018; 6(1): 226.
- 546 34. Caparros-Martin JA, Lareu RR, Ramsay JP, et al. Statin therapy causes gut
- 547 dysbiosis in mice through a PXR-dependent mechanism. *Microbiome* 2017; **5**(1): 95.
- 548 35. Holmes I, Harris K, Quince C. Dirichlet multinomial mixtures: generative
- models for microbial metagenomics. *PLoS One* 2012; **7**(2): e30126.


550






No BAs detected


No BAs detected BAs detected




BAs detected









В





D



100-В ophils 75– utr ne 50of ntage 25-Perc 0 -

Haemophilus Streptococcus Stenotrophomonas Prevotella 7 Veillonella Actinomyces Prevotella Pseudomonas Rothia Staphylococcus

